Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide

被引：0
|
作者：
Lowman, E. [1 ]
Hardigan, P. [2 ]
Unger, N. [3 ]
Lee, N. [1 ]
机构：
[1] Midland Res Grp, Oakland Pk, FL USA
[2] Nova Southeastern Univ, Dr Kiran C Patel Coll Allopath Med, Ft Lauderdale, FL 33314 USA
[3] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P077
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [1] Associations with weight change and patient-reported outcomes after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
    Lowman, E.
    Unger, N.
    Hardigan, P. C.
    Lee, N.
    [J]. HIV MEDICINE, 2020, 21 : 20 - 20
  • [2] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients
    Cicalini, S.
    Lorenzini, P.
    Grilli, E.
    Plazzi, M. M.
    De Zottis, F.
    Camici, M.
    Fusto, M.
    Gagliardini, R.
    Bellagamba, R.
    Antinori, A.
    [J]. HIV MEDICINE, 2021, 22 : 31 - 32
  • [3] Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
    Sax, Paul E.
    DeJesus, Edwin
    Crofoot, Gordon
    Ward, Douglas
    Benson, Paul
    Dretler, Robin
    Mills, Anthony
    Brinson, Cynthia
    Wei, Xuelian
    Collins, Sean E.
    Cheng, Andrew
    [J]. AIDS, 2018, 32 (12) : 1723 - 1725
  • [4] Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo, Alexa B.
    Westmoreland, Drew A.
    Carneiro, Pedro B.
    Johnson, Jeremiah
    Grov, Christian
    [J]. AIDS PATIENT CARE AND STDS, 2021, 35 (08) : 327 - 334
  • [5] The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
    Asif, Sumbul
    Baxevanidi, Evangelia
    Hill, Andrew
    Venter, Willem Daniel Francois
    Fairlie, Lee
    Masenya, Masebole
    Serenata, Celicia
    Sokhela, Simiso
    Chandiwana, Nomathemba
    [J]. AIDS, 2021, 35 : S117 - S125
  • [6] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [7] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
    Ramanathan, Srini
    Custodio, Joseph M.
    Wei, Xuelian
    Wang, Hui
    Fordyce, Marshall
    Dave, Ami
    Ling, Kah Hiing J.
    Szwarcberg, Javier
    Kearney, Brian P.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288
  • [8] Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
    Orkin, C.
    DeJesus, E.
    Ramgopal, M.
    Crofoot, G.
    Ruane, P.
    LaMarca, A.
    Mills, A.
    Van der Cam, B.
    De Wet, J.
    Rockstroh, J.
    Lazzarin, A.
    Rijnders, B.
    Podzamczer, D.
    Thalme, A.
    Stoeckle, M.
    Chu, H.
    Porter, D.
    Liu, H.
    Cheng, A.
    Quirk, E.
    SenGupta, D.
    Cao, H.
    [J]. HIV MEDICINE, 2017, 18 : 21 - 21
  • [9] Efavirenz/emtricitabine/tenofovir disoproxil fumarate - Triple combination tablet
    Frampton, James E.
    Croom, Katherine F.
    [J]. DRUGS, 2006, 66 (11) : 1501 - 1512
  • [10] Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
    Tiraboschi, J.
    Prieto, P.
    Saumoy, M.
    Silva, A.
    Imaz, A.
    Scevola, S.
    Fernandez-Olivares, G.
    Navarro-Alcaraz, A.
    Piatti, C.
    Podzamczer, D.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 79 - 80
12345